About Us

Our Company

Initially founded by Professor John Urquhart in 1984 in Fremont, California; AARDEX Grouphas been the pioneer in medication adherence technology with its development of Medication Event Monitoring Systems (MEMS®). Since then, MEMS® has led the way in accurately describing, measuring, and managing patient adherence behavior in relation to medication.

The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. A major shock is the finding that life-threatening diseases do not, ipso facto, enforce strict adherence. This fact has become more and more evident in many medical fields, some of which include organ transplantation, HIV-AIDS, and more recently in cancer chemotherapy.

Now located in Liège, Belgium, our objective is to continuously innovate to develop efficient and effective solutions for this pervasive problem of striking magnitude in the healthcare system and in clinical trials.

Our mission is to develop ecosystems that seamlessly measure, analyze, and implement patient medication adherence in clinical trials, research settings, and professional healthcare systems to support successful management of patient adherence to medication.

History

1984

Foundation of APREX and generation 1 & 2 of MEMS® hardware technology by John Urquhart.

1989

First MEMS® - based peer-reviewed publication in JAMA

1990

Generation 3 of MEMS® technology

1993

First phase IV clinical study sponsored by Pfizer comparing anti-hypertensive treatmentforgiveness

1994

Generation 4 of MEMS® technology

1998

First audit by a large pharma company (Ely Lilly)

1999

Foundation of AARDEX Group in Switzerland and acquisition of APREX by Dr Jean-Michel Métry.

2001

Generation 5 of MEMS® technology

2002

First ISO9001 compliance certification

2003

Opening of the AARDEX Group research center in Belgium

2004

First FDA filing of MEMS® data from large scale Phase II/III Drug development program for HIV

2005

Generation 6 of MEMS® technology

2005

Launch of medAmigo (currently known as MEMS® Adherence Software)

2007

Creation of the largest repository of dosing history data and the AARDEX Group knowledge center

2010

First deployment of MEMS®adherence hardware and MEMS® adherence software in large scale Drug development of new, all oral, HCV therapies (multi-company, multi-study, multi-country, multi-site)

2012

Acquisition of AARDEX Group by MWV

2014

First large scale adherence-enhancing program based on MEMS®adherence hardware and software in resource-limited setting sponsored by the Bill & Melinda Gates Foundation

2015

MWV merger with Rocktenn to become Westrock

2017

Generation 8 of the MEMS® family of adherence hardware

2018

MBO from WestRock by its CSO, Dr Bernard Vrijens.

2018

HQ of AARDEX Group now operating from Belgium with subsidiary of AARDEX Group in Switzerland

Team

Bernard Vrijens

Bernard Vrijens

CEO & Scientific Lead

David Dalla Vecchia

David Dalla Vecchia

CEO & Financial Lead

Eric Tousset

Eric Tousset

Operational Lead

Jean Michel Biollaz

Jean Michel Biollaz

Software Lead & Director AARDEX Group (Switzerland)

aardex team

Our Customers

Our Customers